SCHEMBL2176697

SCHEMBL2176697

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccc(Cl)cc4Oc4ccccc4)cn3)cc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 6/20 0.51
CSGALNACT1 Q8TDX6 1/20 0.49
P2RY1 P47900 1/20 0.46
SDCBP O00560 2/20 0.40
SDC2 P34741 2/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.38
VHL P40337 1/20 0.37
MAPK1 P28482 4/20 0.36
IGF1R P08069 3/20 0.36
MAPK3 P27361 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13718751 1.00 DGAT1 (0.51) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2181137 0.91 DGAT1 (0.52) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2181145 0.91 DGAT1 (0.52) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2179263 0.86 DGAT1 (0.44) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL13719602 0.86 DGAT1 (0.44) DGAT1CSGALNACT1SDCBPSDC2LMNA
SCHEMBL2355332 0.85 DGAT1 (0.49) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2180786 0.85 DGAT1 (0.49) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2177867 0.85 SDCBP (0.46) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2179929 0.85 SDCBP (0.46) DGAT1CSGALNACT1P2RY1SDCBPSDC2
SCHEMBL2355335 0.83 DGAT1 (0.48) DGAT1CSGALNACT1P2RY1SDCBPSDC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885CSGALNACT1 783/4885P2RY1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.